PMID- 16885935
OWN - NLM
STAT- MEDLINE
DCOM- 20070501
LR  - 20190905
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 32
IP  - 4
DP  - 2007 Apr
TI  - Prior exposure to chronic stress and MDMA potentiates mesoaccumbens dopamine 
      release mediated by the 5-HT(1B) receptor.
PG  - 946-54
AB  - (+) 3,4,-Methylenedioxymethamphetamine (MDMA) is an abused drug that acutely 
      releases serotonin (5-HT) and dopamine (DA) but produces long-term damage to 5-HT 
      terminals. MDMA-induced DA release has been shown to be dampened by 5-HT. 
      Although stress also activates the mesolimbic DA pathway, it is unknown if 
      chronic stress after exposure to neurotoxic doses of MDMA will augment 
      MDMA-induced DA release in the nucleus accumbens shell (NAcc(sh)). Rats were 
      pretreated with MDMA (10 mg/kg x 4, intraperitoneal (i.p.)). After 7 days, rats 
      were subjected to 10 days of chronic unpredictable stress. DA release in the 
      NAcc(sh) and 5-HT in the ventral tegmental area (VTA) were measured after a 
      challenge injection of MDMA (5 mg/kg, i.p.). The combination of pretreatment with 
      MDMA+stress decreased basal concentrations of 5-HT in the VTA and DA in the 
      NAcc(sh) and enhanced MDMA-stimulated DA release in the NAcc(sh). Pretreatment 
      with MDMA or stress alone blunted MDMA-induced 5-HT release in the VTA. The 
      augmentation of MDMA-induced DA release in rats pretreated with MDMA+chronic 
      stress was attenuated by perfusion of the 5-HT(1B) antagonist, GR127935 into the 
      VTA before the MDMA challenge injection. These results suggest that prior 
      exposure to both MDMA and stress can produce a long-term augmentation in 
      mesolimbic DA transmission and enhanced drug abuse vulnerability that is 
      mediated, in part, by the 5-HT(1B) receptor in the VTA.
FAU - Amato, Jennifer L
AU  - Amato JL
AD  - Laboratory of Neurochemistry, Department of Pharmacology, Boston University 
      School of Medicine, Boston, MA 02118, USA.
FAU - Bankson, Michael G
AU  - Bankson MG
FAU - Yamamoto, Bryan K
AU  - Yamamoto BK
LA  - eng
GR  - R01 DA016866/DA/NIDA NIH HHS/United States
GR  - DA 16501/DA/NIDA NIH HHS/United States
GR  - DA 16866/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20060802
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Receptor, Serotonin, 5-HT1B)
RN  - 0 (Serotonin Agents)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Dopamine/*metabolism
MH  - Electrochemistry/methods
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Nucleus Accumbens/*drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Serotonin, 5-HT1B/*physiology
MH  - Serotonin/metabolism
MH  - Serotonin Agents/*pharmacology
MH  - Stress, Physiological/*metabolism/pathology
MH  - Ventral Tegmental Area/*drug effects/metabolism
EDAT- 2006/08/04 09:00
MHDA- 2007/05/02 09:00
CRDT- 2006/08/04 09:00
PHST- 2006/08/04 09:00 [pubmed]
PHST- 2007/05/02 09:00 [medline]
PHST- 2006/08/04 09:00 [entrez]
AID - 1301174 [pii]
AID - 10.1038/sj.npp.1301174 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2007 Apr;32(4):946-54. doi: 10.1038/sj.npp.1301174. Epub 
      2006 Aug 2.